Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment

Debbie Zittema; Niek F. Casteleijn; Stephan J. L. Bakker; Lianne S M Boesten; A A Margreeth Duit; Casper F. M. Franssen; Carlo A. J. M. Gaillard; Ron T. Gansevoort

doi:10.1371/journal.pone.0169263

Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment

Debbie Zittema
, Niek F. Casteleijn
, Stephan J. L. Bakker
, Lianne S M Boesten
, A A Margreeth Duit
, Casper F. M. Franssen
, Carlo A. J. M. Gaillard
, Ron T. Gansevoort

Divison of Internal Medicine and Dermatology

Research output: Contribution to journal › Article › Academic › peer-review

3 Downloads (Pure)

Abstract

BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.METHODS: 15 ADPKD (eGFR

Original language	English
Article number	e0169263
Journal	PLoS ONE [E]
Volume	12
Issue number	1
DOIs	https://doi.org/10.1371/journal.pone.0169263
Publication status	Published - 12 Jan 2017

Keywords

ANTAGONISTS
CYSTIC-DISEASE
DEFECTS
OSMOREGULATION
PLASMA COPEPTIN
POLYCYSTIC KIDNEY-DISEASE
UREA

Access to Document

10.1371/journal.pone.0169263

UrineFinal published version, 1.55 MB

Cite this

@article{83aa3f9393744888bbe226a409a3beb6,

title = "Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment",

abstract = "BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.METHODS: 15 ADPKD (eGFR",

keywords = "ANTAGONISTS, CYSTIC-DISEASE, DEFECTS, OSMOREGULATION, PLASMA COPEPTIN, POLYCYSTIC KIDNEY-DISEASE, UREA",

author = "Debbie Zittema and Casteleijn, \{Niek F.\} and Bakker, \{Stephan J. L.\} and Boesten, \{Lianne S M\} and Duit, \{A A Margreeth\} and Franssen, \{Casper F. M.\} and Gaillard, \{Carlo A. J. M.\} and Gansevoort, \{Ron T.\}",

note = "Publisher Copyright: {\textcopyright} 2017 Zittema et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2017",

month = jan,

day = "12",

doi = "10.1371/journal.pone.0169263",

language = "English",

volume = "12",

journal = "PLoS ONE [E]",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "1",

}

TY - JOUR

T1 - Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment

AU - Zittema, Debbie

AU - Casteleijn, Niek F.

AU - Bakker, Stephan J. L.

AU - Boesten, Lianne S M

AU - Duit, A A Margreeth

AU - Franssen, Casper F. M.

AU - Gaillard, Carlo A. J. M.

AU - Gansevoort, Ron T.

N1 - Publisher Copyright: © 2017 Zittema et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2017/1/12

Y1 - 2017/1/12

N2 - BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.METHODS: 15 ADPKD (eGFR

AB - BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.METHODS: 15 ADPKD (eGFR

KW - ANTAGONISTS

KW - CYSTIC-DISEASE

KW - DEFECTS

KW - OSMOREGULATION

KW - PLASMA COPEPTIN

KW - POLYCYSTIC KIDNEY-DISEASE

KW - UREA

UR - https://www.scopus.com/pages/publications/85009399789

U2 - 10.1371/journal.pone.0169263

DO - 10.1371/journal.pone.0169263

M3 - Article

C2 - 28081165

SN - 1932-6203

VL - 12

JO - PLoS ONE [E]

JF - PLoS ONE [E]

IS - 1

M1 - e0169263

ER -

Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this